1. 283O_PRPhase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer. (23rd October 2018) Authors: Jiang, Z; Li, W; Hu, X; Zhang, Q; Sun, T; Cui, S; Wang, S; Ouyang, Q; Yin, Y; Geng, C; Tong, Z; Cheng, Y; Pan, Y; Sun, Y; Wang, H; Ouyang, T; Gu, K; Feng, J; Wang, X Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers. (27th August 2018) Authors: Chen, X; Li, Y; Ouyang, T; Li, J; Wang, T; Fan, Z; Fan, T; Lin, B; Xie, Y Journal: Annals of oncology Issue: Volume 29:Number 10(2018) Page Start: 2046 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OS2.6 Cerebrospinal fluid (CSF) plays a crucial role in the pathogenesis and treatment of patients with brain metastases. (19th September 2018) Authors: Ali, A; Ouyang, T; Thamburaj, K; Zoccoli, C; Aregawi, D; Zacharia, B; Glantz, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗